Summary--Opioid agonists of the mu, kappa and delta types stimulated low-Km guanosine triphosphatase (GTPase) in membranes, from the brain of the rat by up to 34%, with potencies the rank order of which corresponded to the respective binding affinities to opioid receptor. In general, kappa ligands stimulated GTPase to a lesser degree than mu or delta opiates. The coupling of a given type of opioid receptor to GTPase was resolved by direct or protective alkylation of the other receptors. Treatment of the membranes with I-funaltrexamine abolished the stimulation of GTPase by sufentanil and levorphanol (mu), but not by bremazocine (kappa) or DSLET (delta). On the other hand, prior incubation with Superfit, an alkylating agent with selectivity for the delta opioid receptor, specifically eliminated the effect of DSLET. Partial alkylation by increasing concentrations of Superfit gradually reduced the extent of stimulation of GTPase by DSLET. The successive treatment of membranes with Superfit and /?-funaltrexamine blocked the actions of DSLET, sufentanil and levorphanol, but had no effect on the stimulation of the GTPase by bremazocine.
The binding of agonists to opioid receptors appears to be translated into at least two different, although not necessarily independent, alterations in cell function: an inhibition of the neuronal action potential discharge (Bixby and Spitzer, 1983; Williams and North, 1984) and the inhibition of adenylate cyclase. The interaction of opiates with adenylate cyclase has been described in NG108-15 neuroblastoma x glioma hybrids (Sharma, Nirenberg and Klee, 1975) , slices of brain (Barchfeld, Maassen and Medzihradsky, 1982) and membranes from brain (Law, Wu, Koehler and Loh, 1981) . In addition to causing inhibition of adenylate cyclase, opiates stimulated the activity of a low-Km guanosine triphosphatase (GTPase) in membranes from NG108-15 cells (Koski and Klee, 1981) and rat brain (Barchfeld and Medzihradsky, 1984) . In NG108-15 hybrid cells pertussis toxin inhibited the stimulation of GTPase by opiates, thus suggesting the involvement of the binding protein for GTP (Hildebrandt, Sekura, Codina, Iyenger, Manclark and Birnbaumer, 1983) in the coupling of opioid receptors to adenylate cyclase (Burns, Hewlett, Moss and Vaughan, 1983; Kurose, Katada, Amaro and Ui, 1983) . Considering the requirement of the latter process for GTP (Blume, Lichtshtein and Boone, 1979) , the opiate-sensitive GTPase is causally linked to the mechanism of opioid receptor-effector interaction: the hydrolysis of GTP uncouples the receptor-effector complex. The opioid receptor mediated stimulation of low-Km GTPase in membranes from brain has been described (Barchfeld and Medzihradsky, 1984) . The general characteristics by which opiates stimulated GTPase corresponded to those of their inhibition of adenylate cyclase in cellular preparations from the brain of the rat (Barchfeld et al., 1982) . Recently, differences in the degree and potency by which ligands of the multiple opioid receptors stimulated GTPase in brain were reported (Clark and Medzihradsky, 1985; Clark, Levenson and Medzihradsky, 1986) . In the present work, the stimulation of GTPase by mu, kappa and delta opiates in membranes from brain, alkylated to provide specificity toward a given type of opioid receptor, has been resolved and characterised. of  the  opiates,  including  @-FNA  @-funaltrexamine) and Superfit (cis-( t_ )-3-methylfentanylisothiocyanate) Smith, Jacobson, Burke, Rice and Woods, 19SS) , used in this study were obtained through the Narcotic Drug and Opioid Peptide Basic Research Center, The University of Michigan. UM 1071 R ([IR,5R,9R, 2"R]-5,9-dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-6,7_benzomorphan
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is a benzomorphan derivative with kappa agonist activity (Medzihradsky, DahlStrom, Woods, Fischel and Mitsos, 1984) . ICI 171,864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH; Aib: ~-aminoisobutyric acid) is a highly selective antagonist at the delta opioid receptor (Cotton, Giles, Miller, Shaw and Timms, 1984) 
isolation of membranes
Parts of this procedure have been published previously (Fischel and Med~hradsky, 1981) . Male, Sprague-Dawley rats weighing 200g were decapitated and the brains excised at 4°C. The cerebrum was dissected, washed in Tri-HCl (pH 7.4), blotted and cleaned of adhering blood vessels. The weighed tissue was disrupted for 60 set in 100 vol of ice-cold 50 mM Tris-HC1 (pH 7.4), using a Polytron homogenizer (Model PTlO, Brinkman Instruments Inc., Westbury, New York) at the power output 6.5. The homogenate was centrifuged at 20,000 x g for I5 min in the cold. The pellet obtained was suspended with the original amount of buffer, using a Dounce allglass homogenizer. Aliquots of this suspension, sufficient for experiments on one given day, were frozen at -70°C. Prior to use, the suspension was quickly thawed in a water bath and briefly dispersed in a Dounce homogenizer. The concentration of protein in the latter preparation was approximately 0.5 mg/ml.
Receptor alkylation
For the direct alkylation, the suspension of cerebral membranes in Tris-HCl (pH 7.4), with a concentration of protein of 0.35 mg/ml, was incubated with 100 /IM Superfit for 40 min at 25°C in a shaking water bath. After centrifugation at 20,000 x g for 15 min at 2°C the pellet was suspended in a Dounce homogenizer with the original volume of 50mM . This suspension was then incubated with 200 FM ~-funaltrexamine for 40 min at 25°C in a shaking water bath. After a five-fold dilution with Tri-HCl (pH 7.4), the suspension was centrifuged at 20,000 x g for 15 min at 4°C. The pellet was suspended in 5 original volumes of the Tris buffer and centrifuged as described above. The washing procedure was repeated once more and the pellet suspended in the original volume of Tris-HCl (pH 7.4). The alkylated membranes were either used fresh or frozen in aliquots at -70°C. Freezing and storage had no detectable effects on the results.
For the protective alkylation, the suspension of cerebral membranes in Tris-HCl buffer (pH 7.4), with a protein concentration of 0.3.5mg/ml, was incubated with 800 p M levorphanol or bremazocine, or 400 PM DSLET for 5 min at 25°C. After NaCl and ~~hlornaltrexamine were added to a final concentration of 100 mM and 25 PM, respectively, the suspension was incubated for 40 min at 25°C and then centrifuged at 20,000 x g for 15 min at 2°C. The pellet was suspended in a Dounce homogenizer with 5 original volumes of the Tris buffer, and again centrifuged as described above. The washing procedure was repeated once more, and the final pellet was suspended in the original volume of Tris buffer. An additional washing step had no effect on the parameters of stimulation of GTPase. Aliquots of the membrane suspension were frozen at -70°C.
Assay of GTPase
The assay represented a modification of the previously published procedure (Barchfeld and Medzihradsky, 1984) and was based on the method of Cassel and Selinger ( 1976) . In a final volume of 100 I( 1 the assay medium (in 4ml polypropylene tubes) contained: 0.5 PM ["P]GTP (0.05-0.1 PC per tube), 2-4 fig membrane protein, 12.5 mM Tris-HCI (pH 7.5), 120 mM NaCl, 5 mM MgCl,, 0.1 mM ethylene diamine tetra ammonium (EDTA), 2mM dithiothreitol, 1 mM App(NH)p, 1 mM ouabain, 0.5 mM adenosine triphosphate (ATP), 10 mM creatine phosphate and 5 units creatine kinase. In experiments with dynorphin, the tubes were initially rinsed with 1% bovine serum albumin in 50 mM Tris-HCl (pH 7.4). The opioid ligands were added in IO-20 ~1 of aqueous solutions. In separate tubes, the reaction mixture also contained 50 PM GTP to measure the activity of the opiate-insensitive, high-Km GTPase. The cpm's obtained in the presence of 50 PM GTP were subtracted from the cpm's for total enzyme activity to yield a cpm value representing the activity of the opiate-sensitive, low-Km GTPase.
After the addition of radiolabelled GTP, the samples were incubated for 10 min at 37°C and 1 ml of 25% activated charcoal (suspended at pH 2.3 in phosphoric acid) was added. After standing for 30min in ice, the tubes were centrifuged at 5000 x g for 15 min and 300 ~1 of the supernatant was subjected to liquid scintillation counting. The following controls were routinely included in each assay: basal activity of GTPase in the absence of opiates, hydrolysis of GTP in the absence of membranes and hydrolysis of GTP prior to sample incubation.
Determination of protein
The method of Lowry, Rosebrough, Farr and Randall (1951) was used with bovine serum albumin as standard.
Statistical evaluation of the data
The stimulation of low-Km GTPase in brain was characterized by the parameters KS and S,,,,,. The KS, the ligand concentration producing half-maximal stimulation of basal enzyme activity, was determined by linear regression from plots relating stimulation of GTPase in probits to the log of ligand concentration at 4-5 data points. The S,,,,,, the maximal stimulation of basal low-Km GTPase, was obtained with gradually increasing concentrations of ligand as a well-defined upper limit of enzyme activity. Opioid agonists, present at concentrations greater than that yielding S,,,, , progressively inhibited stimulation of GTPase. The potency of antagonists in inhibiting the stimulation of GTPase was expressed as EC, and was determined from log-probit plots, as described above. The values for KS, S,,,,, and EC,, were expressed as means f standard deviations, based upon 3-6 experiments. The significance of the data was tested by a one-way analysis of variance that compared effects of ligands with control, or for a given ligand, alkylated membranes with no treatment. The results were accepted as different from control if the computed statistic exceeded the corresponding theoretical statistic at the 5% level of significance. The comparison of the means was carried out by the Scheffe test (Scheffe, 1953) .
RESULTS
The rationale for the composition of the GTPase assay medium is described in the original publication by Cassel and Selinger (1976) . The present authors have confirmed 0.5 PM and 50 pMGTP, described by Koski and Klee (1981) , as the optimal concentrations to measure the opiate-sensitive and -insensitive activities of GTPase, respectively. Procedural details of the method described (Koski and Klee, 1981) were modified in order to improve precision, an important aspect considering the limited range of stimulation of the enzyme (Fig. 1) . Initially, the linearity of the enzyme assay with time and protein was established. In addition, it was shown that the basal rate of activity of GTPase in membranes of brain was not altered by the alkylations with /3-funaltrexamine and Superfit. The variability of the basal activity of GTPase (Table 1) reflected the contribution of several preparations of membranes used in this study. Compared to mu opiates, stimulation of low-Km GTPase by kappa ligands was considerably less (Fig. I) . The delta opiate DSLET stimulated GTPase to an extent similar to, or greater than that of mu ligands (Fig. 3) . The rank order of the KS values for stimulation of the enzyme (Fig. I) , correlated with the receptor binding affinities of the respective opiates . For direct alkylation, cerebral membranes of the rat were incubated with IOOpM Superfit or 200pM p-FNA for 40min at 25°C and washed as described under Methods. If treated with both alkylators, incubation with Supertit was followed by washing and treatment with B-FNA. For protective alkylation, the membranes were incubated with 800 pM sufentanil or 400 PM DSLET for 5 min at room temperature. Then N&l and /I-CNA were added to give final concentrations of 100 PM and 25 pM, respectively. After incubation for 40 min at 25"C, the membranes were centrifuged and washed as described. The concentration for half-maximal stimulation (Kd, and maximal stimulation (S,,,) of the basal activity is shown for the opioid agonists levorphanol and sufentanil (mu), bremazocine and dynorphin-(l-13) (kappa) and DSLET (delta), Shown are mean values and standard deviations obtained in 3-5 experiments carried out in triplicate (the experiment with dynorphin was carried out once). The significance of the data relative to the control values (no treatment) was examined by analysis of variance and a comparison test as described under Methods. The statistically different means are indicated by an asterisk. Whereas naloxone blocked the stimulation of GTPase by mu, kappa and delta opiates, the deltaselective opioid antagonist ICI 174,864 specifically inhibited the effect of DSLET (Fig. 2) . In order to resolve the stimulation of GTPase in brain by different types of opioid agonists, siteselective alkylations were carried out. Direct alkylation was accomplished with the mu-and deltaselective irreversible ligands /3-funaltrexamine (Ward, Portoghese and Takemori, 1982) and Superfit (Smith et al., 1985; ). In addition, alkylation with the nonspecific ligand fl-chlornaltrexamine (Ward et al., 1982) , in the presence of protective concentrations of selective mu, kappa and delta opiates, respectively, was implemented. The selective opiates included sufentanil and levorphanol as mu, bremazocine as kappa, and DSLET as delta ligands. Initial alkylation with /Y?-funaltrexamine or Superfit abolished the stimulation of GTPase by mu agonists and delta agonists, respectively (Table 1 ). In addition, alkylation with both p-funaltrexamine and Superfit conveyed specificity to the kappa opioid receptor, as demonstrated by the exclusive stimulation of GTPase by kappa opiates. Selective stimulation of GTPase by mu, kappa or delta opiates was also obtained in membranes treated with /?-chlornaltrexamine in the presence of appropriate ligands (Table 1 ). The concentration of these opiates employed was optimal for protection of receptors, as reflected in the activation of GTPase considering both KS and S,,,,,. Smaller concentrations than those listed resulted in decreased values for S,,, and/or increased Ks, with the latter parameter responding first. As expected, alkylation of membranes with P-chlornaltrexamine alone abolished stimulation of GTPase by any opiate. (Fig. 3) . Whereas 10 PM Superfit had no effect, pretreatment with 100pM of the alkylator abolished the stimulation of enzymatic activity. At all concentrations of Superfit used, the alkylation approximately doubled the co~esponding ZC, value for stimulation of GTPase by DSLET (Fig. 3) . Such impairment in the potency of opiates to stimulate GTPase after alkylation was observed in membranes alkylated by the direct approach, but not after protective alkylations using /3-chlornaltrexamine (Table 1) .
The coupling of multiple opioid receptors to GTPase in brain was resolved into components by the effect of etorphine, a nonselective opioid agonist, after selective alkylation of receptors (Fig. 4) . Stimulation of GTPase induced by the binding of etorphine to the mu and delta receptor was blocked by initial alkylation with B-funaltrexamine and Supetfit, respectively. Each of the two alkylations decreased S,, by approximately 10%. The stimulation of GTPase due to occupancy by etorphine of the kappa receptor was dete~ined in membranes alkylated by both ~-funaltrexamine and Superfit, although again the significance of the kappa effect was difficult to establish. Nonetheless, the sum of the individual components of the stimulation of GTPase in response to the occupancy of the mu, kappa and delta receptors equalled in extent the stimulation by etorphine in non-alkylated membranes (Fig. 4) .
DISCUSSION
Based on its characteristics, the stimulation of high affinity GTPase by opiates represents a functional consequence of occupancy of opioid receptors and reflects the interaction of receptors with the inhibitory guanine nucleotide-binding protein (Ni) (Milligan and Klee, 1985) . The direct involvement of Ni in the function of opiates during their acute (Wuster, Costa, Aktories and Jakobs, 1984) and chronic (Lux and Schulz, 1985) presence has been demonstrated. As shown previously, stimulation of GTPase in mammalian brain was stereospecific, limited to opioid agonists and inhibited by antagonists (Barchfeld and Medzihradsky, 1984) . Contributing to the relatively large concentrations of opiates at which stimula~on of the enzyme occurred (low FM range) was the presence in the assay medium of sodium and GTP which reduced the binding of the agonist to the opioid receptor (Blume, 1978) . Accordingly, antagonists exhibited greater potencies in blocking the stimulation of GTPase than did agonists in causing it (Fig. 2) . The relatively large effective concentrations of the opiates can also reflect impaired coupling of the opioid receptor to the effector in isolated brain membranes, as compared to intact cellular preparations (Barchfeld et al., 1982; Katz and Catravas, 1977) .
In the present work, opiates of all three types stimulated GTPase, although the effect of kappa opiates was of marginal statistical significance. The lesser extent of enzyme stimulation by kappa, relative to mu and delta, ligands corresponds to the low sensitivity of their receptor binding toward the regulation by GTP and Gpp(NH)p (Mack, Lee and Weyhenmeyer, 1985; . Furthermore, the additional coupling of the kappa opioid receptor to an effector system, other than the Niadenylate cyclase complex, e.g. an ion channel (Pfaffinger, Martin, Hunter, Nathanson and Hille, 1985) , cannot be ruled out. It has recently been shown that kappa opiates significantly stimulated GTPase in membranes from the cerebellum of the guinea-pig, a tissue predominantly containing kappa opioid receptors .
Stimulation of GTPase due to ligand occupancy of individual types of opioid receptors was resolved by site-specific alkylations with irreversible ligands, The described selectivity of the stimulation of GTPase complements the resolution of ligand binding to multiple opioid receptors, described previously on the basis of selective opiates (Gillan and Kosterlitz, 1982) , responses to sodium and site-directed alkylation using /I-chlornaltrexamine (James and Goldstein, 1984) . In the present work, both methods of alkylation provided high selectivity to receptor-effecter coupling, i.e. abolished the stimulation of GTPase by ligands of the blocked receptors. However, in contrast to the protective approach, direct alkylation generally increased the KS values of the ligands binding to the receptor to which specificity was conveyed. The increased potency of bremazocine in membranes alkylated with p-funaltrexamine apparently reflected the elimination of the antagonistic component of this opiate at the mu receptor (Von Voigtlander, Lahti and Ludens, 1983) . It is important to note, that the alkylations did not affect the basal rate of the activity of GTPase, and in particular, did not increase it. The approach described here of opioid receptor alkylations yields membranes from brain suitable for the investigation of the selectivity of novel opiates in receptor binding and receptor-effecter coupling (Medzihradsky, 1987) .
The efficiency of the alkylations was also reflected in the quantitative relationships of reoeptor-effector coupling: the multiple components of the stimulation of GTPase, resulting from the occupancy by etorphine of the mu, kappa and delta opioid receptor, respectively, were additive and their sum equalled the total enhancement of enzyme activity determined in unalkylated membranes. In addition, the extent of the stimulation of the enzyme was proportional to the degree of alkylation, although the lack of effect on the activity of GTPase after alkylation with 10 PM Superfit suggests the presence of spare receptors, as demonstrated recently in cerebral membranes of the rat . Such a reserve has previously been shown also to exist in the coupling of the opioid receptor to adenylate cyclase in NGl08-15 neuroblastoma x glioma hybrid cells (Law, Horn and Loh, 1983) .
The described interactions of multiple opioid receptors with an effector component in the mammalian brain, conveniently determined by its enzymatic activity, provide an additional basis for assessing the consequences of ligand binding to receptor. The present authors have studied the efficacy of opiate binding with the focus on GTP binding proteins and are now investigating the relationship between the stimulation of GTPase and the inhibition of adenylate cyclase. On the other hand, the present data do not yet conclusively identify the GTP-binding protein(s) involved in the observed receptor-related stimulation of GTPase. However, the recent availability of specific antibodies to Ni and No, the latter a pertussis toxin sensitive quanine nucleotide-binding protein N.P. 26,12--G present at large concentrations in brain (Gierschik, Milligan, Pines, Goldsmith, Codina, Klee and Spiegel, 1986) , should prove useful in resolving their participation in the phenomena described.
